Doxazosin in elderly patients with hypertension

International Journal of Clinical Practice

Volumn 54, Issue 3, 2000, Pages 181-187,189

  Weinberger, Myron H ^a   Fawzy, A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Urologic Institute of New Orleans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; GLUCOSE; LIPID; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

AGED; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; DRUG INTERACTIONS; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 0343963778     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Cox BD, Blaxter M, Buckle AJL et al. The Health and Lifestyle Survey. London: Health Promotion Research Trust; 1987.
2. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-183.
3. Frost PH, Davis BR, Burlando AJ et al. Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Population (SHEP). Circulation 1996; 94: 2381-2388.
4. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615.
5. Thom TJ, Epstein FH, Feldman JJ et al. Total morbidity and mortality from heart disease, cancer and stroke from 1950 to 1987 in 27 countries: highlights of trends and their interrelationships among causes of death. Washington DC, US DHHS PHS, National Institutes of Health, NIH publ no 92-3088; 1992.
6. Shammas E, Dickstein K. Drug selection for optimal treatment of hypertension in the elderly. Drugs Aging 1997; 11: 19-26.
7. Svanborg A. Age-related changes in cardiac physiology: can they be postponed or treated by drugs? Drugs Aging 1997; 10: 463-472.
8. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure: age and pressure change over time. Hypertension 1991; 18: 67-71.
9. Herrera AH, Davidson RA. Renovascular disease in older adults. Clin Geriatr Med 1998; 14: 237-254.
10. Franklin SS, Gustin W 4th, Wong ND et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
11. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
12. Weaver MT, Mueller RO, Leighton R. Promoting wellness by delaying age of cardiovascular disease onset: development of a model. J Cardiovasc Nurs 1997; 11: 80-92.
13. Nielsen WB, Lindenstrom E, Vestbo J et al. Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens 1997; 10: 634-639.
14. Moye LA, Davis BR, Hawkins CM et al. Conclusions and implications of the systolic hypertension in the elderly program. Clin Exp Hypertens 1993; 15: 911-924.
15. Dahlof B, Hansson L, Lindholm LH et al. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens 1993; 15: 925-939.
16. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967-978.
17. MRC Working Party. Medical Research Council trial on treatment of hypertension in older patients: principal results. BMJ 1992; 304: 405-412
18. Chalmers J. Hypertension in the elderly: benefits of treatment. Blood Press 1995; 3(Suppl): 6-10.
19. Kilander L, Nyman H, Boberg M et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31: 780-786.
20. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592-599.
21. MacConnachie AM, Maclean D. Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Saf 1995; 12: 85-90.
22. Scott PJW, Reid JL. The effect of age on the responses of human isolated arteries to noradrenaline. Br J Clin Pharmacol 1982; 13: 237-239.
23. Stevens MJ, Lipe S, Moulds RFW. The effects of age on the responses of human isolated arteries and veins to noradrenaline. Br J Clin Pharmacol 1982; 14: 750-752
24. Ferrara N, Davia K, Abete P et al. Alterations in beta-adrenoceptor mechanisms in the aging heart: relationship with heart failure. Aging 1997; 9: 391-403.
25. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 179: 1903-1907.
26. Corry DB, Tuck ML. Glucose and insulin metabolism in hypertension. Am J Nephrol 1996; 16: 223-236.
27. Weinberger MH. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Arch Intern Med 1985; 145(6): 1102-1105.
28. Frohlich ED. Treatment guidelines in the USA: hypertension in the elderly. Br J Urol 1998; 1(Suppl 1): 26-28.
29. Ballantyre D. Long-term effects of antihypertensives on blood lipids. J Hum Hypertens 1990; 4(Suppl 2): 35-37.
30. Staessen JA, Thijs L, Gasowski, J et al. Treatment of isolated hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Am J Cardiol 1998; 82(9B): 20R-22R.
31. Weir MR. Non-diuretic-based antihypertensive therapy and potassium homeostasis in elderly patients. Coron Artery Dis 1997; 8: 499-504.
32. Khoury AF, Kaplan NM. Alpha-blocker therapy of hypertension: an unfulfilled promise. JAMA 1991; 266: 394-398.
33. Anderton JL, Notghi A. An evaluation of the efficiency and safety of doxazosin in the treatment of hypertension associated with renal function. J Hum Hypertens 1990; 4(Suppl 3): 52-57.
34. Bartels AC, de Vries PM, Oe LP et al. Doxazosin in the treatment of patients with mild or moderate hypertension and mild to moderate renal insufficiency. Am Heart J 1998; 116: 1772-1777.
35. Huupponen R, Lehtonen A, Vähätalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992; 43: 365-368.
36. Kageyama S, Yamamoto J, Mimura A et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther 1993; 15: 829-837.
37. Dominguez LJ, Weinberger MH, Cefalu WT et al. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. Am J Hypertens 1995; 8: 528-532.
38. Grimm RH Jr, Flack JM, Granditis GA et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension: Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996; 275: 1549-1556.
39. Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131: 966-973.
40. Jardin A, Firby R, Christensen NM et al. Doxazosin is equally well tolerated by older and younger hypertensive men. J Urol 1995; 153: 273A.
41. Langdon CG, Packard RS. Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract 1994; 48: 293-298.
42. Vincent J, Meredith PA, Elliot HL et al. The pharmacokinetics of doxazosin in elderly normotensives. Br J Clin Pharmacol 1986; 21: 521-524.
43. Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28: 223-228.
44. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 29: 7-12.
45. Furuya S, Kumamoto Y, Yokoyama E et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836-839.
46. Landsberg L. Introduction: increased sympathetic nervous system activity in the elderly. Br J Clin Pract 1994; 74(Suppl): 1-743.
47. Kaplan SA. Doxazosin in the older male: efficacy in treating benign prostatic hyperplasia. Eur Urol 1996; 29(Suppl 1): 17-23.
48. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-415.
49. Guthrie RM, Siegel R, and the Hypertension and BPH Intervention Trial (HABIT) Multicenter Study Group. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia (BPH): the Hypertension And BPH Intervention Trial (HABIT). Clin Ther 1999, in press.
50. Kaplan SA, Te AE, Ikeguchi E et al. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years. Br J Urol 1997; 80: 875-879.
51. Lepor H, Kaplan SA, Klimberg I et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525-530.
52. Erley CM. Haefele U. Heyne N et al. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993; 21: 810-815.
53. Wilner KD, Ziegler MG. Effects of alpha inhibition on renal blood and sympathetic nervous activity in systemic hypertension. Am J Cardiol 1987; 59: 82G-86G.
54. Krusell LR, Christensen CK, Pedersen OL. Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term effects of doxazosin. J Cardiovasc Pharmacol 1992; 20: 440-444.
55. Bigazzi R, Blanchi S, Baldari D et al. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-1333.
56. Data on File, Pfizer Inc.
57. Andersson PE, Johansson J, Berne C et al. Effects of selective alpha-1 and beta-1 adrenoceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. Am J Hypertens 1994; 8: 219-226.
58. Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996; 9: 323-333.
59. 2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665-671.
60. + countertransport activity in hypertensive non-insulin dependent diabetic patients: role of insulin resistance and antihypertensive treatment. Metabolism 1997; 46: 1316-1323.
61. Wilde MI, Filton A, Sorkin EM. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3: 258-277.
62. Kaplan SA, D'Alisera PM. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patients: a pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 1998; 53: 201-206.
63. Feher MD, Waller ED. Special patient groups receiving doxazosin. Rev Contemp Pharmacother 1992; 19: 508-519.
64. Scott PJW, Hosie J, Scott MGB. A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients. Eur J Pharmacol 1988; 34: 119-123.